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Chapter 1: Introduction
1. 1

Leishmaniasis
The Trypanosomatid protozoan of the genus Leishmania is the causative agent of

leishmaniasis, a parasitic disease with a prevalence of 12 million cases in 88 countries [1], and a
worldwide incidence o 350 million people at risk of infection [2]. Over 20 species of Leishmania
affect humans, causing three varieties of the diseases, visceral leishmaniasis (VL) affecting the
organs of the body particularly the liver and spleen, mucocutaneous leishmaniasis [3] producing
mucous degeneration, and cutaneous leishmaniasis (CL) [4]. CL caused by Leishmania major is
the most common form of leishmaniasis, affecting the skin and mucous membranes producing
cutaneous ulcers. Even though this disease is consider to be a tropical disease, increased travel
and migration within the tropics, subtropics, Middle East and Southern Europe are making this
disease a risk for population in regions that were unaffected, becoming an emerging concern for
the United States [5].

As of 2006, approximately 2000 U.S. troops stationed in Iraq and

Afghanistan have being diagnosed mostly with CL and a few isolated cases of VL. In addition,
isolated cases of CL have been reported from Border States like Texas, increasing numbers in the
past decade [6].
This disease is transmitted by the bite of infected female phlebotomine sand fly. First,
when a sand fly takes a blood meal, it injects anticoagulants in order to draw blood. During this
process, the sand fly injects the promastigote form from their proboscis into the bloodstream.
Then macrophages and other types of mononuclear phagocytic cells phagocytize promastigotes
that reach the puncture wound. Promastigotes transform in these cells into the tissue stage of the
parasite, amastigotes, which multiply by simple division and proceed to infect other mononuclear
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phagocytic cells. The parasites replicate until the cell burst and are ingested by other phagocytic
cells. Parasite, host, and other factors affect whether the infection becomes symptomatic and
whether cutaneous or visceral leishmaniasis results. Then, a sand fly becomes infected, by
ingesting infected phagocytic cells during blood meals. Within the sand fly’s midgut, the
amastigotes transform into promastigotes and migrate to the proboscis continuing the life cycle
[7]. (Figure 1.1)

Figure 1.1. Transmission and Life Cycle of L. major. 1. Infected sand fly takes a blood meal
and introduces the promastigote form into the bloodstream. 2. Promastigotes are ingested by
phagocytic cells. 3. Promastigotes transform into amastigotes within the phagolysosome of
macrophages. 4. Amastigotes replicate by binary fission within the cell. 5. The cycle is continued
when an infected macrophage is ingested by a sand fly. 6. The parasite emerges from the infected
macrophage. 7. Amastigotes transform and divides in the midgut of the sand fly as
promastigotes. 8. The promastigote migrates to the proboscis where they are ready to be injected
into the host cell. [8]
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Based on this information it can be suggested that leishmaniasis is an emerging concern
in the United States. However, the treatment options available for leishmaniasis are characterized
by high toxicity, and/or low efficacy. Currently, there are three main drugs for the treatment of
leishmaniasis. The most commonly used drugs are pentavalent antimonials with sodium
stibogluconate and meglumine antimoniate [4]. Although these antimonials are effective, they
are highly toxic causing severe side effects such as cardiotoxicity, anemia, pancreatitis, and
reversible renal insufficiency, among others [9]. The second treatment of choice is liposomal
amphothericin B; this drug is FDA approved for the treatment of VL, however it is difficult for
patients to tolerate the treatment for long periods of time. Moreover, it is expensive and required
long course of high dose treatment in order to be effective. Potential side effects such as anemia,
hypokalemia and renal insufficiency may occur in treated patients [10]. In areas where drug
resistance is increasing, the treatment of choice is miltefosine, the only effective oral agent for
leishmaniasis (VL and ML). However, it is not FDA approved, it is also expensive and can
produce side effects such as vomiting and diarrhea [10]. Thus, there is an urgent need for the
development of new chemotherapies against leishmaniasis.
1. 2

Sterol metabolism
Sterols are a fundamental part of the cellular membranes that are necessary for their

normal structure and function. Besides cholesterol, other sterols predominate in eukaryotic
microorganisms such as fungi and protozoa. It is now established that trypanosomatids
synthesize ergosterol and not cholesterol; however, it is absent in the mammalian host cell [11].
It is also known that a very important pathway for trypanosomatids is the sterol biosynthesis
pathway [3]. During this pathway is were ergosterol its produced, which is essential for parasitic
growth and viability [12].
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Cholesterol and ergosterol molecules have a few different characteristics between them.
However, this specific characteristics present in ergosterol and absent in the cholesterol
molecule are essential for the growth and viability of trypanosomatids. For instance, the
presence of two double bonds in the B ring of the steroid nucleus, the presence of a β methyl at
position 24, and the double bond at C22 in the side chain [11]. In addition, for both ergosterol
and cholesterol, the presence of the 3β-OH is necessary for growth, as well as the presence of
methyl groups at C14 and C4 interrupts the growth. Making this two characteristics necessary
for growth [11]. (Figure 1.2)
A

B

Figure 1.2. Molecular structure of ergosterol and cholesterol. A) The arrows indicate the
parts in the ergosterol molecule essential for the growth and viability of the parasite. B)
Cholesterol molecule. [11]
As shown in Figure 1.3, there are several metabolic steps involved in the synthesis of
sterols such as cholesterol and ergosterol, involving specific enzymes in order to be able to
differentiate between microorganisms such as trypanosomatids and mammalian cells. It is known
that azole-type molecules are able to act as sterol biosynthesis inhibitors. Therefore, it is relevant
to take in consideration the synthesis of lanosterol to ergosterol. The first steps involved in the
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synthesis of lanosterol to ergosterol are the demethylation of the ring system at the C14 position
in an oxidative reaction catalyzed by cytochrome P-450 containing the enzyme known as
lanosterol-14α-methyl demethylaze. The removal of 14α-methyl by this enzyme generates an
unsaturated sterol with double bond at the C14. [11]

Figure 1.3. Biosynthesis Pathway of Ergosterol. Each arrow refers to the different metabolic
pathways involved. The sites of action of the sterol biosynthesis inhibitors are underline. [12]

In addition, Leishmania species are highly susceptible to ergosterol biosynthesis
inhibitors, as this sterol is an essential growth factor, as well as the most abundant sterol in the
parasite plasma membrane. Currently, there are several drugs that interfere with sterol
biosynthesis [3] that are in use to treat diseases such as high cholesterol in humans and fungal
infections. Some of these sterol biosynthesis inhibitors (SBIs) are clotrimazole and ketoconazole.
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1. 3

Ruthenium-Azole complexes
The azoles derivatives ketoconazole (KTZ) and clotrimazole (CTZ) have been found to

exert their therapeutic effect through a mechanism involving the inhibition of the biosynthesis of
sterols essential for the parasite, blocking the proliferation of parasites such as Leishmania, and
Trypanosoma cruzi, by inhibiting the cytochrome P-450 dependent C14-demethylation of
lanosterol to ergosterol [13].
Additionally, ruthenium a transition metal of the platinum group, it is known to have
certain properties as an anticancer drug and several biological applications such as the similarity
of ruthenium complexes ligand exchange kinetics to those of platinum antitumor drugs, and
lower toxicity effects because of the ability of ruthenium to mimic the binding of iron to
molecules such as transferrin and albumin [14]. Moreover, ruthenium compounds are also
potential

immunosuppressant’s,

antimicrobials,

anti

malaria

agents,

antibiotics,

and

vasodilator/vasoconstrictor agents [15]. Additionally, ruthenium complexes shows low toxicity
effects towards human cells, as well as the ability to bind to DNA, and mitochondria mediated
apoptosis [16]. Based on all the previous information, ruthenium is potential chemotherapeutic
agent against leishmaniasis.
Moreover, the use of metal-based complexes as chemotherapy agents against the parasite
has shown promise in the development of different types of pharmaceutical agents by
decreasing the toxicity against normal mammalian cells and increasing the activity of the
parental drug.
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1. 4

Hypothesis
Previous generation of Ruthenium-Azole complexes showed promising results against T.

cruzi. [17] [18] In our study, a novel series of Ru-Azole complexes were synthesized and
tested. Based in this evidences and in the literature on Ruthenium complexes behavior we
hypothesized that the Ru-Azole complexes will have higher leishmanicidal activity and lower
cytotoxicity. We speculate that Ru is acting as a carrier to help the azole across the parasite’s
membrane. Once the Ru-Azole complex is inside the parasite is hydrolyzed, releasing the Ru. At
this point the azole will produce its action as sterol biosynthesis inhibitor and the Ru will induce
an apoptotic-like mechanism, subsequently killing the parasite.
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1. 5

Specific Aims

Specific aim 1: In vitro evaluation of the effects of Ru-clotrimazole derivatives on Leishmania
major.
Specific aim 2: In vitro evaluation of the effects of Ru-ketoconazole derivatives on Leishmania
major.
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Chapter 2: In vitro evaluation of the effects of Ru-clotrimazole derivatives on
Leishmania major.

2. 1

Materials and Methods

Culture of Parasite
Promastigotes forms of transgenic L. major Friedlin clone V1 expressing firefly luciferase were
obtain from Dr. Stephen M. Beverley’s lab at Washington University in St. Louis. The parasites
were grown in RPMI 1640 medium supplemented with hemin and 10% inactivated fetal bovine
serum at 56 °C for 30 min and treated with 50 ng/ml streptothricin neosulfate for maintenance of
LUC gene [19].
Culture of Mammalian Cells
Hs27 human fibroblasts (ATCC # HTB-99), RAW 264.7 murine macrophages (ATCC # TIB71), U2OS human osteoblasts (ATTC # HTB-96) (American Type Culture Collection, Manassas,
VA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with
10% inactivated FBS, along with 1% of 10,000 units/ml penicillin and 10mg/ml streptomycin, in
0.9% sodium chloride [20]. Intraperitoneal BALB/c mice macrophages were obtained as
described [21] and cultured in DMEM, supplemented with 10% inactivated FBS along with 1%
of 10,000 units/ml penicillin and 10 mg/ml streptomycin in 0.9% sodium chloride at 37°C. The
procedure was performed minimizing the distress and pain for the animals following the NIH
guidance and animal protocol approved by UTEP’s Institutional Animal Care and Use
Committee (IACUC).
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Synthesis of Ru-azole complexes
Two series of Ru-azole complexes that combine ruthenium with clotrimazole (CTZ) and
ketoconazole (KTZ), were synthesized and purified by appropriate chemical methods at the
Inorganic Chemistry Laboratory of Brooklyn College (CUNY) (R.A. Sanchez-Delgado et al.,
unpublished) [14].
Luciferase Assay
The two series of Ru-azole complexes was screened using L. major strain Friedlin clone V1
expressing firefly luciferase. The drugs (stock solutions in DMSO) were tested in different
concentrations from 30 µM to 0.058 µM. Drugs were transferred (1 µL per well) to 96-well
microplates using an Eppendorf epMotion 5070 automated pipetting system. Promastigotes
(106/well) were added, and parasite survival was measured by luciferase activity with the
substrate 5’-fluoroluciferin (ONE-Glo Luciferase Assay System, Promega) after 96-h incubation
at 28°C, using a luminometer (Luminoskan, Thermo). The bioluminescent intensity was a direct
measure of the survival of parasites. This experiment was performed three times in triplicates,
and the lethal doses (LD50) were determined for each drug. Data was analyzed using GraphPad
Prism Software (Graph Pad Software, Inc., La Jolla, CA).
Evaluation of the Cytotoxicity of Ru-Azole Complexes on Mammalian Cell lines- Alamar Blue
Assay.
Complexes that produced an effective anti-parasitic activity in L. major were further tested using
Alamar Blue assay in the following human mammalian cells: Hs27 human fibroblast, RAW
264.7 murine macrophages, U2OS human osteoblast. Cells were plated as 105 cells per well in a
96 well plate where previously diluted compounds ranging in concentrations from 7.5 µM to
10	
  

0.58 µM were transferred. The cells were incubated for 96/72 hours at 37°C. Additionally, the
compounds were tested in intraperitoneal BALB/c mice macrophages plated at a density of 106
cells per well in a 96 well plate and incubated for 8 hours at 37°C. After this, the compounds
were diluted and then transferred to the plate containing the cells, for an incubation period of 48
hours.
Mammalian cell cytotoxicity of the compounds was analyzed by monitoring the reduction of the
growth medium serving as an indicator of metabolic activity. After each time point, Alamar Blue
reagent (Invitrogen, Carlsbad, California) was added according to the manufacturer’s protocol.
The plates were read using a fluorometer (Flouroskan, Thermo Scientific, Rockford, IL). Data
was analyzed using GraphPad Prism Software (GraphPad Software, Inc., La Jolla, CA).
In vitro evaluation of Ru-Azole Complexes by High-Content Imaging Assay- Infectivity
Experiments.
To mimic the in vivo infection an ex vivo experiment was performed by extracting, mice
peritoneal macrophages as described [21] and cultured in DMEM high-glucose, +L-glu,
supplemented with 10% inactivated FBS, followed by the infection with the metacyclic
promastigotes form of L. major strain Friedlin clone V1. The procedure was performed
minimizing the distress and pain for the animals following the NIH guidance and animal protocol
approved by UTEP’s Institutional Animal Care and Use Committee (IACUC). Mice
intraperitoneal macrophages were placed in a microplate and infected with the metacyclic
promastigotes form of L. major strain Friedlin clone VI, followed by treatment with Ru-Azole
compounds. In a density of 8 x 106, the macrophages were seeded in a 96-well microplate for 8
hr prior to infection. The infection of the macrophage cells will be performed for 24 hr 36 °C 5%
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CO2, at a ratio of 8 parasites per macrophage, in triplicate. After 24 hr, the cells infected with the
amastigotes form of the parasite were washed twice with PBS, and incubated with the
compounds using different concentrations (3.75 µM to 0.029 µM). The cells will be fixed with
4% paraformaldehyde and stained with Alexa Fluor 488 Phalloidin (1.25:100) and DAPI
(1:1000) and the number of infected cells and amastigotes was determined by High-Content
Imaging Assay (HCIA) using a BD Pathway Bioimager microplate confocal microscope [22].
The constrains of five or more parasites per macrophage were used to calculate a z-factor which
indicates the statistical effect of the assay [23].
Statistical Analysis.
The statistical significance (p-value) of the cytotoxicity of the compounds to the promastigote
forms of the parasites and human cells, as well as in the proliferation of the intracellular
amastigotes (HCIA assay), was calculated using the general linear mixed model analysis. This
analysis was used to test the linear effect of the logarithm of dose on the logit transformation of
the percent survival. Each IC50 value was obtained as the exponent of the negative ratio of the γintercept and the slope of the fitted regression line (SAS Software, Version 9.2). To directly
calculate the SE, the nonlinear mixed model was model was used. This method requires the raw
data as the number of parasites that survive (r) and the total number (n) of parasites. In our HCIA
and luciferase assays, we measured the fluorescence or relative luminescence, respectively, from
where the percentage of survival and/or amastigotes per macrophage (not the specific number of
parasites) was calculated. The graphs for display were attained using Graph Pad Prism 5
Software (GraphPad Software, Inc. La Jolla, CA)
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2. 2

Results

In vitro anti-parasitic and cytotoxicity evaluation of Ru-clotrimazole derivatives in mammalian
cells
In these experiments, the effect of eight novel Ru-Clotrimazole compounds was screened
for anti-parasitic and cytotoxic activity in human mammalian cells, in comparison with free CTZ
and with Ruthenium [4] compounds of similar structure but without CTZ (Figure 2.1). The L.
major promastigotes as well as the human osteoblasts were tested at different concentrations (7.5
µM to 0.058 µM) to determine the LD50 after 96 hours treatment periods (Figure 2.2 and 2.3). As
shown in Table 2.1, out of the eight compounds, two of them AM160 and AM162 showed the
best anti-parasitic activity with no toxicity towards mammalian cells. Complex AM160 displays
a high activity against the parasite with an LD50 of 14.63 nM and no toxicity to human
osteoblasts with an IC50 of 7.5 µM. In addition, complex AM162 displays an IC50 of 6.55 µM,
and a LD50 of 450 nM. It is important to mention, that both compounds presents higher
leishmanicidal activity than CTZ alone, and excellent therapeutic index.
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Table 2.1: In vitro antiparasitic activity of the eight novel Ru-clotrimazole compounds and
controls against promastigotes of L. major and cytotoxicity on Human Osteoblasts.

In vitro Infectivity Assay Ruthenium-clotrimazole series
In view of the results obtained against the promastigotes form of L. major and the
cytotoxicity on human osteoblasts, the compounds AM160 and AM162 were tested against the
intracellular form of L. major in infectivity assays for a period of 48 hrs. A high-content imaging
assay (HCIA) was performed on intraperitoneal mice macrophages infected with the metacyclic
promastigotes form L. major to mimic the environment that the compounds would encounter
within an infected mammalian host. Parasite viability was determined by counting the percentage
of infected macrophages with five or more amastigotes per cell. As shown in Figure 2.4,
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complex AM160 was able to decrease the number of infected cells with 5 or more amastigotes
by a 100% with an IC70= 29 nM in comparison with the negative control (1%DMSO); and
complex AM162 an IC40= 1 µM. In Figure 2.5, the representation of BD images of AM160
showed that at concentrations as low as 58.25 nM, AM160 has similar effects than our positive
control Amphothericin B at a higher concentration of 5µM. In addition, both the metal controls
and free CTZ were not able to decrease the percentage of infected cells at concentrations of 1
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Figure 2.4. Effect of AM160 and AM162 on the proliferation of L. major amastigotes infecting
mice intraperitoneal macrophages. The percentage of infected macrophages with five or more
amastigotes was determine using a BD Pathway 855 high-resolution fluorescence bioimager
system. The Z-factor is 0.69 indicating the quality of the assay is excellent. CTZ, Clotrimazol;
C1, C2, C3 metal controls, the graph represent the compounds activities in a concentration range
of 937 to 29.25 nM; □, infected untreated cells; ▲, infected cells treated with 5 µM amphotericin
B.[14]
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1% DMSO

Amp B (5 µM)

AM160 (58.25 nM)

Figure 2.5. Effect of compound AM160 at 58.25 nM, amphotericin B (Amp B) at 5 µM on the
percentage of infected cells against amastigotes L. major. Negative control treated with 1% drug
diluent only.
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Chapter 3: In vitro evaluation of the effects of Ru-ketoconazole derivatives on
Leishmania major.

3. 1

Materials and Methods

Culture of Parasite
Promastigotes forms of transgenic L. major Friedlin clone V1 expressing firefly luciferase were
obtain from Dr. Stephen M. Beverley’s lab at Washington University in St. Louis. The parasites
were grown in RPMI 1640 medium supplemented with hemin and 10% inactivated fetal bovine
serum at 56 °C for 30 min and treated with 50 ng/ml streptothricin neosulfate for maintenance of
LUC gene [19].
Culture of Mammalian Cells
Hs27 human fibroblasts (ATCC # HTB-99), RAW 264.7 murine macrophages (ATCC # TIB71), U2O5 human osteoblasts (ATTC # HTB-96) (American Type Culture Collection, Manassas,
VA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with
10% inactivated FBS, along with 1% of 10,000 units/ml penicillin and 10mg/ml streptomycin, in
0.9% sodium chloride [20]. Intraperitoneal BALB/c mice macrophages were obtained as
described [21] and cultured in DMEM, supplemented with 10% inactivated FBS along with 1%
of 10,000 units/ml penicillin and 10 mg/ml streptomycin in 0.9% sodium chloride at 37°C. The
procedure was performed minimizing the distress and pain for the animals following the NIH
guidance and animal protocol approved by UTEP’s Institutional Animal Care and Use
Committee (IACUC).
Synthesis of Ru-azole complexes
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Two series of Ru-azole complexes that combine ruthenium with clotrimazole (CTZ) and
ketoconazole (KTZ), were synthesized and purified by appropriate chemical methods at the
Inorganic Chemistry Laboratory of Brooklyn College (CUNY) (R.A. Sanchez-Delgado et al.,
unpublished) [14].
Luciferase Assay
The two series of Ru-azole complexes was screened using L. major strain Friedlin clone V1
expressing firefly luciferase. The drugs (stock solutions in DMSO) were tested in different
concentrations from 30 µM to 0.058 µM. Drugs were transferred (1 µL per well) to 96-well
microplates using an Eppendorf epMotion 5070 automated pipetting system. Promastigotes
(106/well) were added, and parasite survival was measured by luciferase activity with the
substrate 5’-fluoroluciferin (ONE-Glo Luciferase Assay System, Promega) after 96-h incubation
at 28°C, using a luminometer (Luminoskan, Thermo). The bioluminescent intensity was a direct
measure of the survival of parasites. This experiment was performed three times in triplicates,
and the lethal doses (LD50) were determined for each drug. Data was analyzed using GraphPad
Prism Software (Graph Pad Software, Inc., La Jolla, CA).
Evaluation of the Toxicity of Ru-Azole Complexes on Mammalian Cell lines- Alamar Blue Assay.
Complexes that produced an effective anti-parasitic activity in L. major were further tested using
Alamar Blue assay in the following human mammalian cells: Hs27 human fibroblast, RAW
264.7 murine macrophages, U2O5 human osteoblasts. Cells were plated as 105 cells per well in a
96 well plate where previously diluted compounds ranging in concentrations from 7.5 µM to
0.58 µM were transferred. The cells were incubated for 96/72 hours at 37°C. Additionally, the
compounds were tested in intraperitoneal BALB/c mice macrophages plated at a density of 106
20	
  

cells per well in a 96 well plate and incubated for 8 hours at 37°C. After this, the compounds
were diluted and then transferred to the plate containing the cells, for an incubation period of 24
hours.
Mammalian cell cytotoxicity of the compounds was analyzed by monitoring the reduction of the
growth medium serving as an indicator of metabolic activity. After each time point, Alamar Blue
reagent (Invitrogen, Carlsbad, California) was added according to the manufacturer’s protocol.
The plates were read using a fluorometer (Flouroskan, Thermo Scientific, Rockford, IL). Data
was analyzed using GraphPad Prism Software (GraphPad Software, Inc., La Jolla, CA).
In vitro evaluation of Ru-Azole Complexes by High-Content Imaging Assay- Infectivity
Experiments.
To mimic the in vivo infection an ex vivo experiment was performed by extracting, mice
peritoneal macrophages as described [21] and cultured in DMEM high-glucose, +L-glu,
supplemented with 10% inactivated FBS, followed by the infection with the metacyclic
promastigotes form of L. major strain Friedlin clone V1. The procedure was performed
minimizing the distress and pain for the animals following the NIH guidance and animal protocol
approved by UTEP’s Institutional Animal Care and Use Committee (IACUC). Mice
intraperitoneal macrophages were placed in a microplate and infected with the metacyclic
promastigotes form of L. major strain Friedlin clone VI, followed by treatment with Ru-Azole
compounds. In a density of 1 x 106, the macrophages were seeded in a 96-well microplate for 8
hr prior to infection. The infection of the macrophage cells will be performed for 24 hr 36 °C 5%
CO2, at a ratio of 10 parasites per macrophage, in triplicate. After 24 hr, the cells infected with
the amastigotes form of the parasite were washed twice with PBS, and incubated with the
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compounds using different concentrations (3.75 µM to 0.029 µM). The cells will be fixed with
4% paraformaldehyde and stained with Alexa Fluor 488 Phalloidin (1.25:100) and DAPI
(1:1000) and the number of infected cells and amastigotes was determined by High-Content
Imaging Assay (HCIA) using a BD Pathway Bioimager microplate confocal microscope [22].
The constrains of five or more parasites per macrophage were used to calculate a z-factor which
indicates the statistical effect of the assay [23].
Statistical Analysis.
The statistical significance (p-value) of the cytotoxicity of the compounds to the promastigote
forms of the parasites and human cells, as well as in the proliferation of the intracellular
amastigotes (HCIA assay), was calculated using the general linear mixed model analysis. This
analysis was used to test the linear effect of the logarithm of dose on the logit transformation of
the percent survival. Each IC50 value was obtained as the exponent of the negative ratio of the γintercept and the slope of the fitted regression line (SAS Software, Version 9.2). To directly
calculate the SE, the nonlinear mixed model was model was used. This method requires the raw
data as the number of parasites that survive (r) and the total number (n) of parasites. In our HCIA
and luciferase assays, we measured the fluorescence or relative luminescence, respectively, from
where the percentage of survival and/or amastigotes per macrophage (not the specific number of
parasites) was calculated. The graphs for display were attained using Graph Pad Prism 5
Software (GraphPad Software, Inc. La Jolla, CA)
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3. 2.

Results

In vitro anti-parasitic and cytotoxicity evaluation of Ru-ketoconazole series in mammalian cells
In these experiments, the effect of six novel Ru-Ketoconazole compounds (Figure 3.1)
was screened for anti-parasitic activity in comparison with free KTZ and with Ru compounds of
similar structure but without KTZ. The compounds were tested at different concentrations (30
µM to 0.058 µM) to determine the LD50 after the treatment for 96 hours (Figure 3.2 ). As shown
in Table 3.1, out of the six compounds three of them A2, A3, and A5 effectively inhibited the
survival of L. major promastigotes by 90% or greater with an LD50 of 0.8 µM, 1.16 µM and 1.53
µM respectively. In addition, the cytotoxic activity of the complexes A2, A3 and A5 was tested
at different concentrations in several mammalian cell lines: U2OS human osteoblasts, Raw 264.7
macrophages, Hs27 fibroblast, and mouse peritoneal macrophages in order to determine the IC50
after the treatment with the compounds. All three compounds (A2, A3, and A5) displayed
minimal to no toxicity when treated against mammalian cells at high concentrations with an
approximate IC50 of 120 µM. As for intraperitoneal mouse macrophages an approximate IC50
>3.75 µM (Figure 3.3 and 12). It is important to mention that Ru-KTZ compounds were able to
double activity than free KTZ.
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Figure 3.1. Chemical structures of Ruthenium-Ketoconazole series.
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Figure 3.2. Effect of KTZ, and complexes A1-A6 on the proliferation of promastigotes of L.
major after 96 hours of treatment.
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Figure 3.3. Effect of A2, A3 and A5 complexes on the cytotoxicity in Human osteoblasts,
Human Fibroblast and Macrophages Raw 264.7 after 72 hours of treatment, and intraperitoneal
macrophages after 24 hours
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Figure 3.4. Effect of A2, A3 and A5 complexes on the cytotoxicity in mouse peritoneal
macrophage after 24 hours of treatment.
25	
  

Table 3.1: In vitro antiparasitic activity of controls and Ru-KTZ complexes against
promastigotes of L. major and epimastigotes of T. cruzi, and cytotoxic activity on mammalian
cells (p-value < 0.0001). Hs27: human fibroblast; U205: human osteoblasts; RAW 264.7: mice
macrophages; IP ɸ: intraperitoneal macrophages.
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In vitro Infectivity Assays: Ruthenium-ketoconazole derivatives.
In view of the results obtained against promastigotes of L. major and the cytotoxicity on
mammalian cells the compounds A2 A3 and A5 were tested against amastigotes of L. major in
infectivity assays for 48 hrs. A high-content imaging assay (HCIA) was performed on
intraperitoneal murine macrophages infected with L. major to mimic the environment that the
compounds would encounter within an infected mammalian host. Parasite viability was
determined by counting the percentage of infected macrophages with five or more amastigotes,
determined using a BD Pathway 855 high-resolution fluorescence bioimager system. As shown
in Figure 3.5, complex A3 was able to decrease the number of infected cells with 5 or more
amastigotes by a 90% at a concentration of 1.87 µM, in comparison with the negative control

Infected Macrophages
w/ 5 or more amastigotes (%)

(1% DMSO). Additionally, complex A2 showed an IC70= 1.87 µM, and A5 an IC50= 3.75 µM.
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Figure 3.5. Effect of A2 A3, and A5 on the proliferation of L. major amastigotes infecting mice
intraperitoneal macrophages. □, infected untreated cells; ▲, infected cells treated with 5 µM
amphotericin B.
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Chapter 4: Discussion

Leishmaniasis is a neglected disease that affects millions of people worldwide. Poor
efficacy and high toxicity of the limited treatment options demonstrate the need for the
development of new chemotherapeutic agents to treat this disease. In order to respond this
concern, the development of novel Ru-azole complexes as chemotherapeutic agents by inhibiting
the cytochrome P-450 dependent C14-α-demethylation of lanosterol to ergosterol which is
essential for the parasite survival. In addition, Ruthenium would enhance the activity of the
parental drug, by helping ketoconazole/clotrimazole to cross the parasite membrane, together
presenting low toxicity. Initially, we used a high-throughput screening approach to evaluate the
cytotoxicity in human osteoblasts and viability of L. major promastigotes of the compounds. To
our satisfaction, the majority of Ru-CTZ complexes displayed potent leishmanicidal activity.
However, only two of them AM162 and AM160 showed no toxicity for mammalian cells and
high activity against the parasite. In addition, compounds AM160 and AM162 showed the
ability to inhibit the survival of L. major intracellular amastigotes in vitro. This experiment is
important because it mimics the host-cell environment and also to be able to determine the
potential activity of a compound in an in vivo model.
Subsequently, we evaluated the efficacy of Ru-ketoconazole complexes. First the
viability of these compounds was tested against the promastigote form of L. major. Out of the six
novel compounds only three compounds A2, A3 and A5 were able to displayed potent
leishmanicidal activity. Based on these results, the cytotoxicity of these two compounds was
tested in RAW 264.7 murine macrophages, human osteoblasts, human fibroblast and
intraperitoneal mouse macrophages, showing no toxicity towards mammalian cells. The effects
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of these compounds on the proliferation of L. major intracellular amastigotes inside the host cell
showed promising results with our best candidate A3 with an IC90= 1.87µM.
In conclusion, based on these experiments Ru-azole complexes represent excellent leads
for the development of new chemotherapeutic agents to treat leishmaniasis.
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